TLR7/8 Antagonist Compounds for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune disorders and diseases related to TLR7/8 overexpression are inadequate, as existing TLR inhibitors do not precisely target TLR7 and TLR8, leading to incomplete immune response modulation.
Innovation Solution
Development of compounds of Formula (I) that act as dual antagonists of TLR7 and TLR8, capable of modulating and inhibiting the activity of these receptors in disease states, thereby providing a targeted approach to treating immune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing TLR inhibitors are used, then immune response modulation is achieved, but target precision for TLR7 and TLR8 is insufficient
Solution Approach 1:
The patent segments the TLR inhibition function into separate selective inhibitors for TLR7 and TLR8, rather than using non-specific broad-spectrum TLR inhibitors. This segmentation allows precise targeting of individual receptors (TLR7 or TLR8) while maintaining effective immune response modulation, directly resolving the contradiction between target precision and modulation effectiveness
Solution Approach 2:
The patent applies local quality by designing compounds with specific molecular characteristics that confer selectivity for particular TLR subtypes (TLR7 or TLR8). The chemical structures are optimized with specific functional groups and structural features that interact preferentially with the binding pockets of target receptors, enabling precise local targeting while maintaining overall immunomodulatory efficacy
2Adaptability or versatility
If broad-spectrum TLR inhibitors are used, then immune response is modulated, but specific inhibition of TLR7 and TLR8 is not achieved
Solution Approach 1:
The patent employs dynamic compound design where the molecular structure can be adjusted and optimized to achieve different selectivity profiles. By modifying functional groups, substituent patterns, and molecular conformation, the compounds can dynamically adapt to target specific TLR subtypes while maintaining immunomodulatory versatility, resolving the contradiction between adaptability and precision
Data Source
AI summary
Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.